The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.
Intellia disclosed that a patient treated with nexiguran ziclumeran as part of the Phase III MAGNITUDE trial has been hospitalized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback